{
  "nctrialId": "HC-1789",
  "title": "A Randomized Open-Label, Active-Controlled Multi-Center Study of PRO-108 (androgen receptor antagonist) in Patients With Advanced Melanoma",
  "officialTitle": "A Randomized Open-Label, Active-Controlled Multi-Center Study of PRO-108 (androgen receptor antagonist) in Patients With Advanced Melanoma",
  "sponsor": "Sunnybrook Research Institute",
  "indication": "Advanced Melanoma",
  "phase": "Phase 4",
  "fileName": "HC-1789.json",
  "fileSize": 380246,
  "date": "2024-10-23",
  "completionDate": "2027-09-03",
  "drugName": "PRO-108 (androgen receptor antagonist)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Terminated",
  "description": "This is a randomized open-label, active-controlled multi-center study designed to evaluate the efficacy and safety of PRO-108 (androgen receptor antagonist) in patients with Advanced Melanoma. The study will enroll approximately 211 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 21-56 years\n- Confirmed diagnosis of Advanced Melanoma\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}